A930005I04Rik Inhibitors
Chemical inhibitors of Myb/SANT-like DNA-binding domain containing 1 utilize various methods to inhibit the activity of this protein. PD98059, U0126, SB203580, and SP600125 target the MAPK pathway at different points; PD98059 and U0126 specifically inhibit MEK1/2 within the MAPK/ERK pathway, which is upstream of ERK, the kinase directly responsible for modulating the activity of Myb/SANT-like DNA-binding domain containing 1. By inhibiting MEK, these compounds prevent the activation of ERK and subsequent regulation of Myb/SANT-like DNA-binding domain containing 1. SB203580 and SP600125, on the other hand, inhibit the p38 MAPK and JNK pathways, respectively, which can also affect the activity of Myb/SANT-like DNA-binding domain containing 1, albeit through different signaling routes within the broad MAPK pathway.
In addition to MAPK pathway inhibitors, other compounds such as LY294002, Wortmannin, and ZSTK474 target the PI3K/AKT pathway, which also has implications for the regulation of Myb/SANT-like DNA-binding domain containing 1. LY294002 and Wortmannin inhibit PI3K, thus reducing AKT signaling and influencing the activity of Myb/SANT-like DNA-binding domain containing 1. ZSTK474 also inhibits PI3K, leading to similar downstream effects. Triciribine directly inhibits AKT, thereby reducing the phosphorylation and activity of proteins involved in DNA binding and regulation. Rapamycin and PP242 focus on the mTOR pathway, with Rapamycin binding to FKBP12 and inhibiting mTOR, and PP242 inhibiting both mTORC1 and mTORC2 complexes, which affects the activity of proteins that regulate cell growth and Myb/SANT-like DNA-binding domain containing 1. Lastly, Palbociclib inhibits CDK4 and CDK6, kinases involved in cell cycle progression, which may influence the activity of Myb/SANT-like DNA-binding domain containing 1. Similarly, Dasatinib, an SRC family kinase inhibitor, disrupts multiple kinases and thereby impacts signaling pathways that regulate Myb/SANT-like DNA-binding domain containing 1. Each of these inhibitors engages with a specific molecular target, leading to a reduction in the regulatory activity of Myb/SANT-like DNA-binding domain containing 1 through distinct but converging biochemical pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which is part of the MAPK/ERK pathway. Myb/SANT-like DNA-binding domain containing 1 is regulated by ERK signaling, and inhibition of MEK by PD98059 would suppress ERK activation, leading to the inhibition of Myb/SANT-like DNA-binding domain containing 1 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 acts as an inhibitor of MEK1/2, impairing the MAPK/ERK pathway. Since Myb/SANT-like DNA-binding domain containing 1 activity is influenced by ERK signaling, the inhibition of MEK1/2 by U0126 would result in decreased activation of ERK and consequent inhibition of Myb/SANT-like DNA-binding domain containing 1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, which indirectly inhibits the AKT pathway. The AKT pathway can regulate DNA-binding proteins like Myb/SANT-like DNA-binding domain containing 1, and the inhibition of PI3K by LY294002 would reduce AKT signaling and inhibit Myb/SANT-like DNA-binding domain containing 1 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin acts as an inhibitor of PI3K, leading to the inhibition of the AKT pathway. Given that Myb/SANT-like DNA-binding domain containing 1 is regulated in part by AKT signaling, Wortmannin's inhibition of PI3K would lead to decreased AKT activity and functional inhibition of Myb/SANT-like DNA-binding domain containing 1. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits AKT phosphorylation and activation. By inhibiting AKT, triciribine would reduce the phosphorylation of substrates involved in DNA binding and transcription regulation, such as Myb/SANT-like DNA-binding domain containing 1, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, a downstream target of AKT. By inhibiting mTOR, Rapamycin would decrease the activity of certain transcription regulators, which could include Myb/SANT-like DNA-binding domain containing 1, thereby inhibiting its function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib inhibits CDK4 and CDK6, which are crucial for cell cycle progression and may influence the activity of DNA-binding proteins. The inhibition of these kinases by Palbociclib would lead to the inhibition of cell cycle-related functions of Myb/SANT-like DNA-binding domain containing 1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAPK. Since p38 MAPK can influence the activity of various DNA-binding proteins, the inhibition of p38 MAPK by SB203580 would lead to the inhibition of Myb/SANT-like DNA-binding domain containing 1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK pathway. The inhibition of JNK by SP600125 would affect the activity of proteins regulated by the JNK pathway, leading to the inhibition of Myb/SANT-like DNA-binding domain containing 1. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is an SRC family kinase inhibitor which also affects several other kinases. By inhibiting SRC kinases, Dasatinib would disrupt signaling pathways that regulate transcription factors and DNA-binding proteins, resulting in the inhibition of Myb/SANT-like DNA-binding domain containing 1. | ||||||